Vita Coco enters its third-quarter report with a stark disconnect between the business and its stock. Management has raised its full-year sales outlook three times in a row, closed its first meaningful acquisition and expanded its buyback. Shares have still fallen about 26% since the last report, while the S&P 500 gained roughly 5%. The October 22 release, due before the open, is the first quarter in which the company's warned-about cost inflation fully meets its booming demand. That makes it a real test of which force the market has been pricing.

The Street is looking for earnings of $0.51 per share on revenue of $232.1 million. Both figures are up about 27% from a year ago, which is strong growth for a staples name. The sequential picture looks less flattering. Last quarter's $0.82 included roughly 700 basis points of gross margin from tariff refunds that will not recur. Analysts are therefore modeling a normalization, not a slowdown. The more striking gap is on the top line for the full year. Management now guides 2026 sales to $790 million to $805 million, while consensus sits near $746 million. That is below even the low end of the company's own range. Part of the gap likely reflects the Copra acquisition, which management expects to exceed $100 million in annual sales, not being fully reflected in Street models. A third quarter that shows Copra contributing alongside organic strength would make the guidance look credible rather than aspirational.

The central operating question is gross margin. Management said second-half margins would fall below the roughly 49% achieved in the first half. Its reasons were packaging, domestic logistics and energy inflation starting in mid-third quarter, a richer private-label mix, and ocean freight surcharges, only about half of which were locked in. The full-year target of about 40% implies a meaningful step down from here. Investors should judge the quarter against that roadmap, not against the inflated first half. A margin in the low 40s with costs tracking to plan would validate management's framing. A sharper drop, or a new admission that freight and packaging are running hotter than expected, would raise the stakes on the 2027 price increases management floated.

Demand is the less contested part of the story, but it still needs proof. The company lifted its U.S. private label growth outlook from 20% to 25% at the start of the year to 90% to 100% last quarter. That jump was driven by regained regions and a new tetra account. International sales rose 63% in the second quarter. Club promotional timing that shifted between quarters could also flatter or distort third-quarter shipments. The constraint is supply. Plants were running near 95% utilization, and an earthquake at the General Santos facility cost about 1% of annual network capacity. Any sign that shortages capped shipments would cut both ways. It would confirm demand, but it would also suggest guidance leaves little room for error.

Sentiment has cooled modestly, with bullish readings slipping from about 26% to 22%. The stock sits at $57.61, below its 200-day moving average of $61.42. That leaves it in the lower part of its post-earnings range of roughly $50 to $80. Expectations, in other words, have been reset lower even as fundamentals were marked higher.

The narrative holds if Vita Coco shows that the margin step-down is the orderly, pre-announced one rather than the start of an open-ended squeeze. It also needs to show that Copra and private label keep the full-year sales range intact. Clear evidence on costs, along with a reaffirmed or raised outlook, would challenge the market's skepticism. Margin slippage beyond plan would suggest the stock's slide was the early signal.